title: Expression of the tumor-rejection antigen SART1 in brain tumors.
abstract: We have reported a tumor-rejection antigen, SART1(259), possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1(259) antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1(259) antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain-tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA-A24-restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1(259)+ glioma cells, and the levels of recognition correlated both with HLA-A24-antigen expression level and with the concentration of the SART1 peptide antigen. Therefore, the SART1(259) antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA-class-1 antigens.
authors.affiliation: Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Imaizumi
authors.forename: T
authors.initials: T
authors.lastname: Kuramoto
authors.forename: K
authors.initials: K
authors.lastname: Matsunaga
authors.forename: S
authors.initials: S
authors.lastname: Shichijo
authors.forename: S
authors.initials: S
authors.lastname: Yutani
authors.forename: M
authors.initials: M
authors.lastname: Shigemori
authors.forename: K
authors.initials: K
authors.lastname: Oizumi
authors.forename: K
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D001932:Brain Neoplasms / Q000737:chemistry* / Q000276:immunology* / Q000473:pathology / Q000556:secondary; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000737:chemistry* / Q000276:immunology* / Q000473:pathology; D015234:HLA-A Antigens / Q000032:analysis; D059871:HLA-A24 Antigen; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006801:Humans; D007167:Immunotherapy; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis*; D017411:Ribonucleoproteins, Small Nuclear; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D015395:Histocompatibility Antigens Class I; D009363:Neoplasm Proteins; D017411:Ribonucleoproteins, Small Nuclear; C431323:SART1 protein, human